Nitrazepam Neuraxpharm (Nitrazepam)

Nitrazepam binds to the benzodiazepine site on the GABA‑A receptor, enhancing the effect of the inhibitory neurotransmitter GABA. This increases chloride ion influx, hyperpolarising neurons and reducing overall central nervous system excitability, which produces its sedative, anxiolytic and anticonvulsant actions.

The appropriate dose of Nitrazepam Neuraxpharm is determined by the prescribing clinician based on the individual’s medical condition, age, response to therapy and any concurrent medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for nitrazepam in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nitrazepam shares the core mechanism of GABA‑A modulation with other benzodiazepines but has a relatively long half‑life, which can provide prolonged hypnotic effect. Compared with shorter‑acting agents, it may be preferred for insomnia where sustained sleep is needed, but the longer duration also raises the risk of next‑day sedation.

Nitrazepam Neuraxpharm should be stored at room temperature, below 25 °C, in its original packaging. The container should be kept tightly closed, protected from moisture, heat and direct sunlight to maintain product stability.

Nitrazepam Neuraxpharm is administered orally, typically as a tablet taken with or without a small amount of water. The exact timing—such as before bedtime for insomnia—should follow the prescriber’s guidance.

Serious risks include respiratory depression, severe hypotension, profound sedation, paradoxical reactions such as agitation, and the potential for dependence or withdrawal syndrome upon abrupt discontinuation. Patients should be monitored closely for these events, especially when initiating therapy or adjusting doses.

Nitrazepam is contraindicated in individuals with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, and in patients who are currently abusing alcohol or other CNS depressants. Caution is also advised for the elderly and those with significant hepatic or renal impairment.